Dow Jones Newswires: Enhertu significantly delayed breast cancer progression in trial, AstraZeneca says

AstraZeneca PLC said Monday that its Enhertu drug significantly delayed metastatic breast cancer progression in a Phase 3 trial, reinforcing the results of a prior trial.

The Anglo-Swedish pharma giant
AZN,
+1.96%
said results from the Destiny-Breast02 Phase 3 trial of Enhertu–trastuzumab deruxtecan–showed the trial met the primary endpoint, demonstrating a significant and clinically meaningful improvement in progression-free survival in patients.